Compare Enveric Biosciences Inc (ENVB) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Royal Caribbean Cruises Ltd — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Royal Caribbean Cruises Ltd trades at $307.5 (market cap $82.38B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 13287.1× Enveric Biosciences Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.62% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | RCL | |
|---|---|---|
Market Cap | $6.20M | $82.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $365.84 |
52-Week Low | $1.27 | $246.71 |
Enterprise Value | $1.30M | $105.02B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Royal Caribbean Group (RCL) trades at $320, down 0.17% on the day, with a bullish technical signal and strong fundamental momentum. The stock is supported by robust earnings beats, with Q2 2026 EPS of $4.21 exceeding the $3.98 estimate, and a consensus analyst price target of $343.09 implying upside. Recent news highlights strong demand, fleet expansion, and a $1.25 billion senior notes offering to fund growth, while cash flow trends show improving operational strength.
The outlook for RCL remains positive, driven by record bookings, pricing power, and strategic investments, though risks include geopolitical impacts on European itineraries, high debt levels, and premium valuations. Investors should weigh the company's solid execution against macroeconomic and industry-specific headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
